Clinical Edge Journal Scan

Rimegepant lowers MMDs and tablet use and improves HRQoL in migraine


Key clinical point: Rimegepant on a patient treated as needed (PRN) basis reduces monthly migraine days (MMD) without increasing the monthly tablet use and improves health-related quality of life (HRQoL) in patients with acute migraine.

Major finding: Rimegepant reduced the mean MMD from 10.9 days at baseline to 8.9 days by week 52 and led to an increase of 0.08 quality-adjusted life years. The mean monthly tablet use decreased from 7.9 tablets to 7.3 tablets between weeks 4-8 and 48-52.

Study details: This was a post hoc analysis of the phase 2/3 safety BHV3000-201 study including 1,044 patients with a ≥1-year history of migraine and ≥6 MMD who received 75 mg rimegepant up to once daily PRN for up to 52 weeks.

Disclosures: The study was sponsored by Biohaven Pharmaceuticals. CP Schreiber reported being a speaker for various organizations, including Biohaven. The rest of the authors are employees and stock/stock option owners of Biohaven or Broadstreet HEOR (funded by the former).

Source: Johnston K et al. J Headache Pain. 2022;23:10 (Jan 17). Doi: 10.1186/s10194-021-01378-5

Next Article: